Clicky

KalVista Pharmaceuticals, Inc.(KALV)

Description: KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.


Keywords: Pharmaceutical Disease Organ Systems Eye Enzymes Stage Pharmaceutical Diabetic Macular Edema Macular Edema Hereditary Angioedema Angioedema Complement Deficiency Kallikrein C1 Inhibitor Kinin–Kallikrein System Plasma Kallikrein Protease Inhibitor

Home Page: www.kalvista.com

KALV Technical Analysis

55 Cambridge Parkway
Cambridge, MA 02142
United States
Phone: 857 999 0075


Officers

Name Title
Mr. Thomas Andrew Crockett M.B.A. CEO & Director
Mr. Benjamin L. Palleiko Chief Bus. Officer & CFO
Dr. Christopher M. Yea Ph.D. Chief Devel. Officer
Dr. Edward P. Feener Ph.D. Chief Scientific Officer
Jarrod Aldom VP of Corp. Communications
Ms. Rachel M. Morten Sr. VP of Regulatory Affairs & QA
Dr. Michael D. Smith Pharm.D. Sr. VP of Devel.
Dr. Paul K. Audhya M.B.A., M.D. Chief Medical Officer
Mr. Stephen Donnelly Director of Fin. and Company Sec.
Mr. John B. McKune VP of Fin.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9792
Price-to-Sales TTM: 107.4168
IPO Date: 2015-04-09
Fiscal Year End: April
Full Time Employees: 105
Back to stocks